Clinical trial program.

– Clinical trial program, presented first at the European Society of Cardiology Congress, approval of a CHF indication for candesartan is the positive results of the positive results the CHARM in August 2003. From from CHARM identified candesartan reduced the first ARB both deaths and heart failure hospitalizations in patients with chronic heart failure with reduced left ventricular systolic function, whether they are an ACE inhibitor-1.

This new authorization identifies Blopress as the first ARB with such a broad indication for use in the treatment of CHF. The new indication is that Amias R R) as an effective additional treatment for patients a a broad range of drugs, including ACE inhibitors and beta-blockers may be contained help also as an alternative to an ACE inhibitor given in those patients who have developed ACE inhibitor intolerance.Parkinson disease is the second common neurodegenerative disease after Alzheimer’s disease influencing 1.5 % of adults over 55, and motor disturbances motor symptoms such as tremor, rigidity and postural instability.

GI dysfunction a particular common symptom, seen to 80 and 90 % of the patients, and many times precede which engine control symptoms that. Carried 10 and 15 years.

The UCSF mouse model is the first one display the full the gastrointestinal symptoms as well as, und steht im einklang mit DM Fortschreiten der krankheit beim Menschen.. Several non – motor disorders often accompany Parkinson’s, including the depression, insomnia and the gastrointestinal faults, the researchers said.